OncoMatch/Clinical Trials/NCT05366478
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
Is NCT05366478 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Autologous tumor infiltrating lymphocytes (TILs) for melanoma.
Treatment: Autologous tumor infiltrating lymphocytes (TILs) — This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Small Cell Lung Cancer
Cervical Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
lymphocyte ratio > 20%; neutrophil count > 1.0 × 10^9/L; WBC > 3.0 × 10^9/L; platelets > 100 × 10^9/L; hemoglobin > 80 g/L
Kidney function
urea ≤ ULN x 1.5; creatinine ≤ ULN x 1.5
Liver function
ALT and AST ≤ ULN x 2.5 (≤ ULN x 5 if liver metastasis); ALP ≤ ULN x 2.5; TBIL ≤ ULN x 1.5
Cardiac function
LVEF ≥ 50%
Laboratory inspection index requirements: ... Blood routine: lymphocyte ratio > 20%; neutrophil count > 1.0 × 10^9/L; white blood cells > 3.0 × 10^9/L; platelets > 100 × 10^9/L; hemoglobin > 80 g/L; Liver function: ALT and AST ≤ ULN x 2.5 (≤ ULN x 5 if liver metastasis); ALP ≤ ULN x 2.5; TBIL ≤ ULN x 1.5; Renal function: urea ≤ ULN x 1.5; creatinine ≤ ULN x 1.5; Cardiac: LVEF ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify